Trial Profile
A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs HI-con1 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Iconic Therapeutics
- 23 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 May 2014 New trial record
- 16 Apr 2014 Iconic Therapeutics has completed a successful phase I trial in the US and is planning an international phase II study, according to a company media release.